Follistatin is a myostatin-pathway antagonist. The published muscle-mass corpus is real but Tier 3. Gene-therapy trials are different programs from the RUO peptide vendors sell. Construct nomenclature matters. RUO research reference.
For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
Disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full FTC disclosure on the About page.
Follistatin is an endogenous glycoprotein that binds and neutralizes members of the TGF-β superfamily — most importantly myostatin (also called GDF-8), the negative regulator of skeletal muscle mass that, when knocked out, produces the famously hyper-muscled mouse and double-muscled cattle phenotypes.
Category: muscle-pathway research compound. Same conversation as the GH secretagogue class on the muscle-mass side, but a different mechanism — the secretagogues drive GH and IGF-1 upward; follistatin pulls a brake off the myostatin pathway.
The single-line summary: myostatin-pathway antagonist via direct binding. Pull the brake; muscle growth signaling runs less restricted.
The complication that makes this page longer than it would otherwise be: "follistatin" in research peptide markets refers to several different constructs, and at least three different programs in the broader follistatin space are not the same thing. We have to separate them before the literature is interpretable.
Se-Jin Lee at Johns Hopkins / University of Connecticut is the foundational author here. Lee's lab established the myostatin gene and its role as a negative regulator of muscle growth in the 1990s. The follistatin-binds-myostatin biology and the demonstration that follistatin overexpression produces increased muscle mass in animal models comes out of the same research program and its collaborators. Search "Se-Jin Lee myostatin follistatin" on PubMed for the foundational corpus.
The pathway, in plain English: Myostatin is a TGF-β family ligand secreted by skeletal muscle. It binds the activin type II receptor (ActRIIB) on muscle, activates Smad2/3 signaling, and tells muscle to stop growing. Follistatin binds myostatin in circulation and prevents it from reaching its receptor. With follistatin elevated, the negative signal is muted and net muscle protein accretion runs higher.
Follistatin also binds activin A (a related TGF-β family ligand) and several BMPs, which is why describing it as "purely a myostatin antagonist" is not quite right. The molecule is promiscuous across the family. That promiscuity is part of why the safety profile is harder to characterize than it would be for a clean myostatin-only antagonist.
One nomenclature term worth unpacking, because this is where most operator confusion lives:
When a vendor lists "follistatin" without specifying construct, the operator does not actually know which molecule is in the vial. This is more upstream than the dosing conversation.
Half-life. Reported in the moderate range for circulating endogenous follistatin (FST-315) — hours, not minutes — though the published pharmacokinetic record for synthetic research-peptide constructs in humans is thin and varies by isoform. FST-288 is shorter-lived in circulation than FST-315 by design.
Route. Subcutaneous injection is the dominant administered route in research-peptide contexts. Intramuscular and intra-articular routes appear in some animal-model work. Note: the AAV gene-therapy programs use viral-vector delivery to muscle tissue — this is not a route operators administering a synthetic peptide are using, and conflating them is the most common error in community discussion of "follistatin trials."
The Compound's Tier framework: Tier 1 is large human RCTs. Tier 2 is smaller human studies or strong animal work in disease-relevant models. Tier 3 is mechanistic and preclinical. Tier 4 is hypothesis and N=1.
For follistatin, the tiering depends entirely on which program you are looking at.
Follistatin is one of the molecules in the founder-operator stack where the gap between hope and corpus is the widest, and the community discussion reflects that.
Hypertrophy reports. N=1 reports of muscle gain on follistatin protocols are noisy. Some users report visible body composition change over weeks; others report nothing. The signal is not as clean as the GH secretagogue class produces, and is much messier than the mouse data would predict.
Construct ambiguity in vendor product. Community discussion frequently surfaces that "follistatin" purchased from different vendors is qualitatively different — different reconstitution behavior, different reported subjective effects. Whether this reflects actual construct differences (FST-288 versus FST-315 versus mislabeled material) or potency variance at the bench is unclear and is one of the COA conversations that matters most for this molecule.
Conflation with gene therapy. A persistent error in community framing is to cite the AAV-FS-344 trial results as evidence for the synthetic peptide. The two programs are mechanistically and pharmacokinetically different. Operators who are careful about this distinction read the literature differently than operators who are not.
Stacking with recovery peptides. Pairing with BPC-157 and TB-500 is common in community recovery-and-hypertrophy stacks. The mechanism overlap is partial — recovery peptides act on tissue-repair signaling, follistatin on growth-suppression antagonism — but the use patterns coincide.
PIP and site reactions. Reported as moderate; lot-to-lot variance is part of the chatter.
A short list.
The Compound covers follistatin in the muscle-pathway arc of the briefing, alongside the GH secretagogue class (MK-677, CJC-1295/ipamorelin) and adjacent to the recovery-peptide group (BPC-157, TB-500, GHK-Cu) where stack overlaps are most common. It is one of the molecules where the curator's job is more "separate the programs" than "summarize the literature" — and that separation is the point of the briefing.
Related issues: Issue 1 — the muscle-pathway primer.
Related compounds: BPC-157, TB-500, GHK-Cu, MK-677, CJC-1295 / Ipamorelin.
If you came here from a recovery-and-hypertrophy framing, the more directly useful read is the recovery-and-injury stack guide. It is the operator-grade summary of how the recovery-peptide group (BPC-157, TB-500, GHK-Cu) and the muscle-pathway group sit next to each other in working stacks — and where the literature still doesn't show what the stack post implies.
Get the guide: thecompoundbrief.com/recovery-injury-stack
The Sunday briefing on peptides for founder-operators. One email. What's new in the literature, what survived peer review, what moved up or down on the operator stack, and the cited summaries that fit better behind the email gate than on a public page like this one.
Subscribe at thecompoundbrief.com.
For research use only. This page is a literature reference for research purposes. Nothing on it is medical advice, and nothing on it is a recommendation to administer, prescribe, or self-administer any compound discussed.
FDA disclaimer. None of the statements on this page have been evaluated by the U.S. Food and Drug Administration. Synthetic follistatin peptide is not approved for human use in the United States. Research compounds are not intended for human consumption.
FTC disclosure. The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Editorial coverage on this site is independent of vendor selection. Full disclosure on the About page.
No medical advice. Consult a qualified medical professional before making any decisions about your health, medications, or supplementation.
BPC-157, TB-500, and the recovery lane — what the literature actually shows.
Download the PDF →